Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer E-Book


344 pages
Lire un extrait
Obtenez un accès à la bibliothèque pour le consulter en ligne
En savoir plus


Each volume in the Early Detection and Treatment of Cancer Series is packed with practical, authoritative information designed to cover the full range of diagnostic procedures, including pathologic, radiologic, bronchoscopic, and surgical aspects. You’ll be able to determine the safest, shortest, least invasive way to reach an accurate diagnosis; stage the disease; and choose the best initial treatment for early stages. Based on current evidence in the literature, authors provide clinical, hands-on tools to help you make informed decisions on precisely what tests and imaging studies are needed to diagnose and stage each type of cancer. Practical, authoritative, and highly-illustrated, this volume in the brand new Early Detection and Treatment of Cancer series covers current protocols and the latest advances in diagnostic imaging and molecular and serologic markers for colon cancer. Apply expert advice on the best “next-step plan for different presentations and tips for less invasive protocols. Get clinical, hands-on tools to help you make informed decisions on precisely what tests and imaging studies are needed for accurate diagnosis and staging. Clear figures, tables, and boxes illustrate step-by-step care of the full range of problems encountered. The small size and convenient format make this an ideal purchase for diagnostic reference.
  • Outlines the steps after diagnosis to guide you through formulating a treatment or patient care plan.
  • Emphasizes important points—such as risk-adjusted screening for staging and the use of promising new gene therapies—with “key points boxes at the beginning of each chapter and pedagogic features throughout.
  • Summarizes the process of accurately diagnosing and staging cancer in a logical, almost algorithmic, approach for easy reference.
  • Complements the procedures outlined in the text with full-color photographs and line drawings to reinforce your understanding of the material.


United States of America
Management of cancer
Myocardial infarction
S-formylglutathione hydrolase
Colorectal polyp
Tumor antigen
Total mesorectal excision
New Zealand
Systemic therapy
Blood in stool
Behaviour therapy
Missense mutation
Annual report
Surgical oncology
Germline mutation
Hip replacement
Familial adenomatous polyposis
Cancer staging
Inflammatory bowel disease
Deep vein thrombosis
Rectal examination
Physician assistant
Lower gastrointestinal series
Bowel obstruction
Genetic testing
Health care
Heart failure
Clinical trial
Pulmonary embolism
Colorectal cancer
Advance health care directive
Randomized controlled trial
List of surgical procedures
Medical ultrasonography
Ulcerative colitis
Crohn's disease
X-ray computed tomography
Radiation therapy
Positron emission tomography
Magnetic resonance imaging
Laparoscopic surgery


Publié par
Date de parution 15 juillet 2010
Nombre de lectures 0
EAN13 9781437735642
Langue English
Poids de l'ouvrage 21 Mo

Informations légales : prix de location à la page 0,0421€. Cette information est donnée uniquement à titre indicatif conformément à la législation en vigueur.

Signaler un problème

Early Diagnosis and
Treatment of Cancer
Colorectal Cancer
Series Editor: Stephen C. Yang, MD
Edited by
Susan L. Gearhart, MD
Assistant Professor of Colorectal Surgery and Oncology
Department of Surgery
The Johns Hopkins University
Baltimore, Maryland
Nita Ahuja, MD
Assistant Professor of Surgery and Oncology
Department of Surgery
The Johns Hopkins University
Baltimore, Maryland
Breast Cancer
Edited by Lisa Jacobs and Christina A. Finlayson
Colorectal Cancer
Edited by Susan L. Gearhart and Nita AhujaHead and Neck Cancer
Edited by Wayne M. Koch
Ovarian Cancer
Edited by Robert E. Bristow and Deborah K. Armstrong
Prostate Cancer
Edited by Li-Ming SuTable of Contents
Cover image
Title Page
Series Preface
1 Epidemiology and Risk Factors of Colorectal Cancer
Risk Factors
Economic Burden of Disease
2 Presentation and Initial Evaluation of Colorectal Cancer
Initial Evaluation
3 Hereditary Colorectal Cancer and Polyp SyndromesIntroduction
Hereditary Nonpolyposis Colorectal Cancer
Familial Adenomatous Polyposis
MYH-Associated Polyposis
APC I1307K Mutation
Juvenile Polyposis Syndrome
Familial/Juvenile Polyposis Coli
Cowden Syndrome
Bannayan-Riley-Ruvalcaba Syndrome (Bannayan-Zonana Syndrome)
Peutz-Jeghers Syndrome
4 Genetic Screening
Proper Use of Clinical Genetic Testing
The Genetic Counseling Process
Genetic Testing for Colorectal Cancer Syndromes
Genetic Testing for Juvenile Polyposis
5 Behavior and Dietary Modification in the Prevention of Colon Cancer
Vitamins and Micronutrients
6 Chemoprevention of Colorectal Cancer
Nonsteroidal Anti-inflammatory DrugsUrsodeoxycholic Acid
Minerals and Vitamins
Diet and Exercise
7 Fecal Occult Blood Test
Types of Fecal Occult Blood Tests
General Advantages and Disadvantages of Fecal Occult Blood Tests
Specific Characteristics of the g-FOBT and FIT
8 Colonoscopy and Flexible Sigmoidoscopy in Colorectal Cancer Screening and
Indications for Screening
Findings on Endoscopic Evaluation
Screening and Surveillance Tools
Current Recommendations
Special Populations
New Directions
9 Stool and Blood Sampling for Early Detection of Colorectal Cancer
Screening Blood
Screening StoolConclusion
10 Radiologic Techniques: Virtual Colonoscopy
Principles and Supporting Literature
Interpretation Strategies
Current Controversies
Reimbursement Issues
Future Directions
11 Preoperative Evaluation
Preoperative Preparation
Specific Medical Considerations
Postoperative Analgesia
12 Limited Resection: Indications, Techniques, and Outcomes of Transanal Excision
and Transanal Endoscopic Microsurgery
Long-term Outcomes After Local Excision
Patient Selection
Operative Techniques
Radical Resection Immediately After Local Excision
Follow-up and Salvage Therapy After Local Excision
References13 Endoscopic Techniques in Colorectal Neoplasia
Endoscopic Resection
Colorectal Self-Expandable Metal Stents
14 Open Surgical Techniques in Colorectal Cancer
Surgical Oncologic Principles: Historical Perspective
Oncologic Principles for Bowel Resection and Margins
Staging the Extent of Cancer Resection
15 Systemic Therapy for Colon Cancer
Metastatic Colorectal Cancer
Duration of Therapy
Adjuvant Systemic Therapy
Future Directions
16 Radiation Therapy for Colorectal Adenocarcinoma: External Beam and
Intraoperative Radiation Therapy
External Beam Radiation Therapy for Rectal Cancer
Intraoperative Radiation Therapy: Overview
HDR-IORT for Locally Advanced Rectal Cancer
Locally Recurrent Rectal Cancer
Re-irradiationIORT Toxicity
Functional Outcome and Quality of Life
Role of Adjuvant EBRT in Locally Advanced Colon Cancer
Conclusions and Future Directions
17 Surveillance and Follow-up
Overview of Prospective Evidence
Frequency and Duration
History and Physical Examination
Carcinoembryonic Antigen Testing
Computed Tomography
Positron Emission Tomography
18 Clinical Trials: Why Participate?
Types of Clinical Trials
Phases of a Clinical Trial
Clinical Trial Designs
Participation in a Clinical Trial
Multicenter Clinical Trial
19 Vaccines and Immunotherapy
Immunotherapy—An Overview
Immunotherapy and Metastases
20 Genetic Profiling in Colorectal Cancer
Types of Genetic Profiling
Practical Issues in Genetic Profiling
Future Directions
21 Coping with Colorectal Cancer
Physical and Psychosocial Aspects of Colorectal Cancer
Perspective and Concerns of the Patient
Types of Cancer Support Resources
Other Considerations After a Diagnosis of Colorectal Cancer
Late Effects versus Long-Term Side Effects of Cancer Treatment
What Is It Like to Be a Cancer Survivor?
The Caregiver's Perspective
22 Conclusion
1600 John F. Kennedy Boulevard
Suite 1800
Philadelphia, PA 19103-2899
ISBN-13: 978-1-4160-4686-8
Copyright © 2011 by Saunders, an imprint of Elsevier Inc.
No part of this publication may be reproduced or transmitted in any form or by any
means, electronic or mechanical, including photocopying, recording, or any
information storage and retrieval system, without permission in writing from the
publisher. Details on how to seek permission, further information about the
Publisher's permissions policies and our arrangements with organizations such as the
Copyright Clearance Center and the Copyright Licensing Agency, can be found at our
website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under
copyright by the Publisher (other than as may be noted herein).
N otices
Knowledge and best practice in this field are constantly changing. As new research
and experience broaden our understanding, changes in research methods,
professional practices, or medical treatment may become necessary.
Practitioners and researchers must always rely on their own experience and
knowledge in evaluating and using any information, methods, compounds, or
experiments described herein. In using such information or methods they should
be mindful of their own safety and the safety of others, including parties for whom
they have a professional responsibility.
With respect to any drug or pharmaceutical products identified, readers are advised
to check the most current information provided (i) on procedures featured or (ii) by
the manufacturer of each product to be administered, to verify the recommended
dose or formula, the method and duration of administration, and contraindications.
It is the responsibility of practitioners, relying on their own experience and
knowledge of their patients, to make diagnoses, to determine dosages and the best
treatment for each individual patient, and to take all appropriate safety
To the fullest extent of the law, neither the Publisher nor the authors, contributors,
or editors, assume any liability for any injury and/or damage to persons or property
as a matter of products liability, negligence or otherwise, or from any use or
operation of any methods, products, instructions, or ideas contained in the materialherein.
Library of Congress Cataloging-in-Publication Data
Early diagnosis and treatment of cancer: colorectal cancer / edited by Susan L.
Gearhart, Nita Ahuja.
p. ; cm.—(Early diagnosis and treatment of cancer series)
Includes bibliographical references and index.
ISBN 978-1-4160-4686-8
1. Colon (Anatomy)—Cancer. 2. Rectum—Cancer. I. Gearhart, Susan L. II. Ahuja,
III. Series: Early diagnosis and treatment of cancer series.
[DNLM: 1. Colorectal Neoplasms—diagnosis. 2. Colorectal Neoplasms—therapy. 3.
Early Diagnosis. WI 529 C719035 2010]
RC280.C6C6627 2011
Acquisitions Editor: Dolores Meloni
Design Direction: Steven Stave
Early Diagnosis and Treatment of Cancer
Series Editor: Stephen C. Yang, MD
Breast Cancer
Edited by Lisa Jacobs and Christina A. Finlayson
Colorectal Cancer
Edited by Susan L. Gearhart and Nita Ahuja
Head and Neck Cancer
Edited by Wayne M. Koch
Ovarian Cancer
Edited by Robert E. Bristow and Deborah K. Armstrong
Prostate Cancer
Edited by Li-Ming Su
Print in the United States of America
Last digit is the print number: 9 8 7 6 5 4 3 2 1D e d i c a t i o n
This book is dedicated to all the patients with colorectal cancer that we have had the privilege
to treat. Your courage in facing this disease inspires us to continue to seek a cure for colorectal
cancer both as surgeons and as scientists.$
Series Preface
S een on a graph, the survival rate for many cancers resembles a precipice. D iscovered
at an early stage, most cancers are quickly treatable, and the prognosis is excellent. I n
late stages, however, the typical treatment protocol becomes longer, more intense,
and more harrowing for the patient, and the survival rate declines steeply. N o
wonder, then, that one of the most important means in fighting cancer is to prevent
or screen for earlier stage tumors.
Within each oncologic specialty, there is a strong push to identify new, more useful
tools for early diagnosis and treatment, with an emphasis on methods amenable to an
office-based or clinical se ing. These efforts have brought impressive results.
A dvances in imaging technology, as well as the development of sophisticated
molecular and biochemical tools, have led to effective, minimally invasive approaches
to cancer in its early stages.
This series, Early D iagnosis and Treatment of Cancer, gathers state-of-the-art research
and recommendations into compact, easy-to-use volumes. For each particular type of
cancer, the books cover the full range of diagnostic and treatment procedures,
including pathologic, radiologic, chemotherapeutic, and surgical methods, focusing
on questions like these:
▪ What do practitioners need to know about the epidemiology of the disease and its
risk factors?
▪ How do patients and their families wade through and interpret the myriad of
▪ What is the safest, quickest, least invasive way to reach an accurate diagnosis?
▪ How can the stage of the disease be determined?
▪ What are the best initial treatments for early-stage disease, and how should the
practitioner and the patient choose among them?
▪ What lifestyle factors might affect the outcome of treatment?
Each volume in the series is edited by an authority within the subfield, and the
contributors have been chosen for their practical skills as well as their research
credentials. Key Points at the beginning of each chapter help the reader grasp the
main ideas at once. Frequent illustrations make the techniques vivid and easy to
visualize. Boxes and tables summarize recommended strategies, protocols,
indications and contraindications, important statistics, and other essential
information. Overall, the a empt is to make expert advice as accessible as possible to
a wide variety of health care professionals.
For the first time since the inception of the N ational Cancer I nstitute's annual
status reports, the 2008 “A nnual Report to the N ation on the S tatus of Cancer,”
published in the D ecember 3 issue of the Journal of the N ational Cancer Institute, noted
a statistically significant decline in “both incidence and death rates from all cancerscombined.” This mark of progress encourages all of us to press forward with our
efforts. I hope that the volumes in Early D iagnosis and Treatment of Cancer will make
health care professionals and patients more familiar with the latest developments in
the field, as well as more confident in applying them, so that early detection and
swift, effective treatment become a reality for all of our patients.
Stephen C. Yang MD The Arthur B. and Patricia B. Modell, Professor of
Thoracic Surgery, Chief of Thoracic Surgery, The Johns Hopkins Medical Institutions:
P r e f a c e
I n the United S tates, colorectal cancer ranks as the third most common cancer in both
incidence and death for both men and women. I n 2009, an estimated 146,970 new
patients were diagnosed with colorectal cancer, and 49,920 colorectal cancer-related
deaths occurred. Worldwide, colorectal cancer has an estimated incidence of 1.02
million cases, making it the third most common cancer. The highest incidences of
colorectal cancer have been reported in N orth A merica, Australia/N ew Zealand, and
Western Europe, with the lowest incidence in parts of Africa and Asia.
Recent advances have made the future of colorectal cancer patients more
promising. Colorectal cancer is considered to be a disease that goes in a stepwise
progression from normal colon to adenoma and then to invasive cancer. Knowledge
of this stepwise progression presents an opportunity to intervene and identify
preinvasive lesions using endoscopic techniques and population-wide screening. The
introduction of widespread screening in the United S tates occurred in the 1970s and
1980s, when researchers demonstrated the feasibility of testing for occult blood in
stool and initiated randomized clinical trials. I n 1985, the diagnosis of colon cancer in
President Ronald Reagan led to increased public awareness of this disease. Finally,
the introduction of Medicare reimbursement for all individuals in 2001 led not only to
improvements in adherence to screening guidelines but also to increased likelihood
of diagnosing the cancer at an early stage.
This volume on Early Diagnosis and Treatment of Cancer: Colorectal Cancer is meant as
an introduction to the current understanding of the epidemiology, risk factors, and
treatment options for colorectal cancer. Like the rest of this series, this book is
designed to provide up-to-date information regarding safe and effective methods to
reach a diagnosis, obtain accurate clinical staging of the disease, and choose the best
method of treatment.
I ncluded in this volume are discussions of hereditary colon cancer syndromes,
indications for genetic screening, and potential chemoprevention methods. S ince the
stage of diagnosis is the most significant predictor of outcome, the book includes
several chapters on screening techniques for early diagnosis of colorectal cancer. The
book is also designed to guide the reader in formulating a logical, step-by-step
treatment or patient care plan. Each chapter regarding treatment is comprehensive
and timely, and key points emphasize the important aspects of each individual step in
the process.
We thank the contributors—all leaders in their respective fields—for their
dedication and tireless efforts in pu ing together this volume. We hope that the book
will serve as an important resource guide for health care providers who strive to
improve the lives of patients with both early and advanced stages of colorectal cancer.
Finally, this volume is dedicated to all our patients with colorectal cancer who
continue to inspire us to seek a cure.Susan L. Gearhart MD, Nita Ahuja MDContributors
Nita Ahuja MD, Assistant Professor of Surgery and Oncology, Department of
Surgery, The Johns Hopkins University, Baltimore, Maryland
Vanita Ahuja MD, MPH, Associate Program Director, York Hospital–Wellspan
Health, York, Pennsylvania
Debashish Bose MD, PhD, Fellow, Department of Surgical Oncology, The
University of Texas MD Anderson Cancer Center, Houston, Texas
David Chang MPH, PhD, Johns Hopkins University School of Medicine, Baltimore,
Kathryn M. Chu MD, MPH, Clinical Assistant Professor, Johns Hopkins University
School of Medicine, Baltimore, Maryland
Stephanie R. Downing MD
General Surgery, Department of Surgery, Howard University Hospital, Howard
University College of Medicine, Washington, DC;
Research Associate, Department of Surgery, Johns Hopkins University School of
Medicine, Baltimore, Maryland
Khaled El-Shami MD, PhD, Assistant Professor of Oncology and Medicine,
Lombardi Comprehensive Cancer Center at Georgetown University; Attending
Oncologist, Georgetown University Hospital, Washington, DC
Susan L. Gearhart MD, Assistant Professor of Colorectal Surgery and Oncology,
Department of Surgery, The Johns Hopkins University, Baltimore, Maryland
Francis M. Giardiello MD, John G. Rangos Sr. Professor of Medicine, Johns
Hopkins University School of Medicine, Baltimore, Maryland
Samuel A. Giday MD, Robert E. Meyerhoff Professor, Director, Endoscopic
Ultrasound Unit, Division of Gastroenterology and Hepatology, Johns Hopkins
University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland
Joseph M. Herman MD, MSc
Assistant Professor of Radiation Oncology,
The Johns Hopkins University School of Medicine, Baltimore, Maryland
Karen M. Horton MD, Professor of Radiology, The Russell H. Morgan Department
of Radiology and Radiological Science, Johns Hopkins Medical Institutions,
Baltimore, Maryland
Matthew T. Hueman MD, FACS, Assistant Professor of Surgery, Uniformed
Services University; Surgical Oncologist and Associate Program Director, General
Surgery, Department of Surgery, Walter Reed Army Medical Center, Washington, DC
Ajay Jain MD, Assistant Professor of Surgery, University of Maryland Medical
Center, Baltimore, MarylandMichel I. Kafrouni MD
Gastroenterology, Johns Hopkins Hospital, Baltimore, Maryland;
Private Practice, Gastroenterology Consultants, P.A., Houston, Texas
John H. Kwon MD, Assistant Professor, University of Chicago, Chicago, Illinois
Wells Messersmith MD, Assistant Professor, Director, GI Cancers Program,
University of Colorado Denver, Denver, Colorado
Melissa A. Munsell MD, Associate Physician, Southern California Permanente
Medical Group, Anaheim, California
Jamila Mwidau MD, Johns Hopkins University School of Medicine, Baltimore,
Sujatha Nallapareddy MD, Developmental Therapeutics and GI Malignancies,
University of Colorado Denver, Denver, Colorado
Emmanouil P. Pappou MD, Department of Surgery, The Johns Hopkins University
School of Medicine, Baltimore, Maryland
Timothy M. Pawlik MD, MPH, Associate Professor of Surgery and Oncology,
Johns Hopkins University, Johns Hopkins Hospital, Baltimore, Maryland
Cheryl J. Pendergrass MS, CGC, Genetic Counselor, The Johns Hopkins University
School of Medicine, Baltimore, Maryland
Nicole A. Phillips BS, University of Chicago, Chicago, Illinois
Richard Schulick MD, Professor of Surgery and Oncology, Chief, Cameron Division
of Surgical Oncology, Johns Hopkins University, Baltimore, Maryland
Eun Ji Shin MD, Assistant Professor of Medicine, Johns Hopkins University School
of Medicine, Baltimore, Maryland
Jason K. Sicklick MD, Chief Administrative Fellow, Department of Surgery,
Memorial Sloan-Kettering Cancer Center, New York, New York
Jerry Stonemetz MD, Clinical Associate, Johns Hopkins Medical Institutions,
Baltimore, Maryland
Eden R. Stotsky BSN, RN, Nurse Clinician, Johns Hopkins Hospital, Baltimore,
Susan Tsai MD, Surgical Oncology Fellow, Johns Hopkins Medical Institutions,
Baltimore, Maryland
Elizabeth C. Wick MD, Assistant Professor of Colorectal Surgery, Johns Hopkins
University; Attending Surgeon, Johns Hopkins Hospital, Baltimore, Maryland
Michelle N. Zikusoka MD, Department of Medicine, Johns Hopkins University,
Baltimore, Maryland1
Epidemiology and Risk Factors of
Colorectal Cancer
Kathryn M. Chu
• Colorectal cancer (CRC) is the third most common cancer and the third most common cause of cancer
death in the United States.
• Over the past 20 years, the incidence of CRC has declined.
• Developed countries have a higher incidence of CRC than do developing countries.
• Adenocarcinoma is the most common type of CRC.
• Persons over 50 years of age have the greatest risk for CRC.
• A higher incidence of CRC is found among blacks than among other races.
• Men have a slightly higher risk of developing CRC than do women.
• Known risk factors for CRC include family history, obesity, poor diet, alcohol and cigarette use, and
lack of exercise.
Types of Colon and Rectal Cancer
1S everal types of primary cancer are located in the colon and rectum. These include adenocarcinoma,
carcinoid tumor, gastrointestinal stromal tumor, lymphoma, and squamous cell cancer of the anus. The
majority (95%) of cancers of the colon and rectum are adenocarcinomas or tumors arising from intestinal
glands. The epidemiology of this type of tumor is discussed in this chapter. Metastases to the colon and
rectum are rare but can occur with melanoma and breast cancer. Carcinoid tumors arise more commonly in
the small bowel and appendix, although on occasion these tumors can be identified in the rectum (Fig.
11A). Carcinoid tumors develop from gastrointestinal neuroendocrine cells. Gastrointestinal stromal tumors
develop from interstitial cells of Cajal and can be found anywhere in the gastrointestinal tract (Fig. 1-1B).
Lymphoma may originate in the colon and rectum but is more commonly found in the lymphatic system.
Squamous cell cancer of the anus is associated with human papilloma virus infection (Fig. 1-1C).FIGURE 1-1 A, Carcinoid tumor of the rectum. B, Gastrointestinal stromal tumor of
the colon. C, Squamous cell cancer of the anus. D, Adenocarcinoma of the colon.
Incidence of Adenocarcinoma of the Colon and Rectum
Colorectal cancer (CRC) is found throughout the world, but the incidence of this disease varies widely (Fig.
1-2). D eveloped countries have a higher incidence of CRC than do developing countries, with the highest
incidences occurring in Australia, N orth A merica, and N orthern and Western Europe. The United S tates
has one of the highest rates of CRC in the world. The incidence is almost 10-fold lower in parts of A frica
2,3and Asia.FIGURE 1-2 Age-standardized incidence rates per 100,000 for colorectal cancer by
gender. (From Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002.
CA Cancer J Clin 55:74–108, 2005.)
4,5CRC is the third most common cancer in the United S tates for men and women (Fig. 1-3).
A pproximately 147,000 people (76,000 men and 71,000 women) will be diagnosed in 2010 (Fig. 1-4). The
incidence of CRC has been decreasing over the last 20 years. I n 2004, the reported incidence of CRC was
48.2 per 100,000, whereas in 1985 the reported incidence was 66.3 per 100,000. This decline is believed to be
4,5related to an increase in screening for CRC (detection and removal of colorectal polyps), although
changes in lifestyle may also play a role.FIGURE 1-3 A, Age-adjusted cancer incidence rates for various cancers in men in the
United States, 1975–2004. B, Age-adjusted cancer incidence rates for various cancers
in women in the United States, 1975–2004. Data are age adjusted to the 2000 United
States standard population and adjusted for delays in reporting. (From Cancer
Statistics, 2008. American Cancer Society Statistics on Cancer 2008.)FIGURE 1-4 Leading sites of new cancer cases and deaths in the United States by
gender, 2009 estimates. (From Cancer Facts and Figures 2009. © 2009, American
Cancer Society, Inc. Surveillance Research.) American Cancer Society, Inc.
Stage at Time of Diagnosis
There are several historical colorectal staging systems, including the D ukes and A stler-Coller systems. The
6most widely used staging system is the TN M system of the A merican J oint CommiAee on Cancer (A J CC).
I n this system, the four stages are based on the depth of invasion of the primary tumor (T), lymph node
status (N ), and distant metastasis (M) (Table 1-1 and Box 1-1). A pproximately 39% of colon and rectum
cancer cases are diagnosed while the cancer is still confined to the primary site (localized stage or stage
I /I I a), 36% are diagnosed after the cancer has spread to regional lymph nodes (stage I I I ) or directly beyond
the primary site (stage I I b), 19% are diagnosed after the cancer metastasized (distant stage or stage I V),
5and for 5% the staging information is unknown. The most common site of metastasis for stage I V CRC is
the liver."
Table 1-1
American Joint Committee on Cancer Staging of Colorectal Cancer
Stage T N M
Stage I T1–2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T4a N0 M0
Stage IIC T4b N0 M0
Stage IIIA T1–2 N1 M0
T1 N2a M0
Stage IIIB T3–4 N1 M0
T2–3 N2a M0
T1–2 N2b M0
Stage IIIC T4a N2a M0
T3–4a N2b M0
T4b N1–2 M0
Stage IVA Any T Any N M1a
Stage IVB Any T Any N M1b
Adapted from Greene FL: AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010, p 199. Springer
11 A merican J oint C ommi ee on C ancer T N M C lassification of C olorectal
C ancer
Primary Tumor (T)
T0 No evidence of primary tumor
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through muscularis propria into pericolorectal tissue
T4a Tumor penetrates the surface of the visceral peritoneum
T4b Tumor directly invades or is adherent to other organs or structures
Regional Lymph Nodes (N)
N0 No invasion of regional lymph nodes
N1a Invasion into one regional lymph node
N1b Invasion into two to three regional lymph nodes
N1c Tumor deposits without invasion into regional lymph nodes
N2a Invasion into four to six regional lymph nodes
N2b Invasion into seven or more regional lymph nodes
Distant Metastasis (M)
M0 No distant metastasis present
M1a Single distant metastasis
M1b Multiple distant metastasis7I n recent years, a greater proportion of CRC has been diagnosed at earlier stages. This shift reflects the
trend toward increased and improved screening. Gross and associates demonstrated that when Medicare
began to reimburse for screening colonoscopy in 1998, a significantly higher percentage of cancers were
8diagnosed at an early stage (stage I).
Location of Primary Tumor
A pproximately 30% of CRC is located in the right colon, 10% in the transverse colon, 15% in the left
(descending) colon, 25% in the sigmoid colon, and 20% in the rectum (Fig. 1-5). I n the past 20 years,
9–12epidemiologic studies have shown that the ratio of proximal to distal cancers has been increasing. This
is due to a slight increase in proximal cancers and a decrease in cancers of the descending colon and
rectum. Older persons are more at risk for proximal lesions (Fig. 1-6), and the aging and growing
population has contributed to this increase. The decrease in distal cancers is likely due to improved
screening of the sigmoid and rectum.
FIGURE 1-5 Distribution of colon and rectal cancer. (From Hopkins Colon Cancer
website. Used with permission from author, Michael Choti, MD.
pg=disease1&organ=6&disease=36&lang_id=1. Digestive Diseases Library—Colon
Cancer. Sporadic Colon Cancer. Accessed June 24, 2007.)FIGURE 1-6 The right shift of colorectal cancer with age. (From Saltzstein SL,
Behling, CA: Age and time as factors in the left-to-right shift of the subsite of colorectal
adenocarcinoma: A study of 213,383 cases from the California Cancer Registry. J Clin
Gastroenterol 41(2):173–177.)
Risk Factors
A lthough much has yet to be learned about why some individuals develop colon cancer and others do not,
certain factors are known to increase a person's chance of developing the disease. These factors are both
genetic and environmental.
Genetic Factors
Personal or Family History of Colorectal Cancer
A family history of CRC increases the likelihood that an individual will develop CRC. A prospectiv estudy
of 119,116 individuals examined the relative risk of developing CRC for those with a first-degree relative
with a history of CRC compared with those with unaffected relatives. The age-adjusted relative risk of CRC
was 1.7. The relative risk among individuals with two or more affected first-degree relatives was 2.7. For
13those younger than 45 years who had one or more affected first-degree relatives, the relative risk was 5.4.
Most patients with CRC who also have a family history of CRC do not have a genetically inherited
syndrome. Overall, genetically inherited syndromes that cause CRC such as hereditary nonpolyposis colon
cancer (HN PCC) and familial adenomatous polyposis (FA P) are rare (5% to 10%) F(ig. 1-7). These
syndromes are discussed in Chapter 3, Hereditary Cancer S yndromes. A personal history of CRC increases
14a person's risk of developing another CRC.FIGURE 1-7 Contribution of familial and hereditary causes to colorectal cancer
cases. FAP, familial adenomatous polyposis; HNPCC, hereditary nonpolyposis colon
cancer. (From http://www1.geneticsolutions.com/?id=4338:22210. Lynch and de la
Chapelle, 2003. © Clinical Tools, Inc.) Clinical Tools, Inc.
Personal History of Inflammatory Bowel Disease
A personal history of inflammatory bowel disease (ulcerative colitis or Crohn's disease) increases a
person's risk of CRC. I ndividuals with primary sclerosing cholangitis, severe longstanding disease, and
15–17young age at diagnosis have the highest risk. I n a meta-analysis of 19 studies, the cumulative risk of
18CRC for those with ulcerative colitis was 2% at 10 years, 8% at 20 years, and 18% at 30 years. The extent of
disease is also associated with an increased risk of CRC. I n a population-based cohort study of 3117
persons in S weden with ulcerative colitis, the odds of developing CRC for isolated proctitis was 1.7
compared with 2.8 for left-sided colitis and 14.8 for pancolitis. Moreover, for those with pancolitis of more
than 35 years' duration, the risk of CRC was 30%. For those with pancolitis for more than 35 years, which
19was diagnosed before the age of 15 years, the risk was 40%.
A ge is a significant risk factor for CRC, with more than 90% of cases developing after age 50. The median
5age at diagnosis is 73 years for colon cancer and 67 years for rectal cancer. A lthough the overall incidence
of CRC is decreasing in the United States, some evidence suggests that its incidence among younger people
is increasing. Moreover, younger individuals often present with more advanced disease and poorly
20differentiated tumors than do older adults.
21Men have a slightly higher risk of developing colon cancer compared with women (odds ratio = 1.4). This
22risk is more pronounced in rectal cancer (odds ratio = 1.7). From 2001 to 2005, the incidence of CRC was
559.2 per 100,000 for men compared with 43.8 per 100,000 for women.
S ignificant racial disparities exist in CRC (Fig. 1-8). There is a higher incidence in blacks compared with
5whites (62.1 versus 51.2 per 100,000), whereas A sian and Pacific I slanders have the lowest incidence of all
5ethnic groups. Blacks are more likely to be diagnosed at an earlier age and with a more advanced stage of
23disease. The reasons for these racial disparities are still being investigated. Certain racial and ethnic
minorities may have lower rates of screening and poorer access to care.FIGURE 1-8 Age-adjusted incidence rates by race for colon and rectal cancer in the
United States, 2000–2004. (Data from the Surveillance, Epidemiology, and End Results
Program, http://www.seer.cancer.gov. Accessed May 1, 2007.)
Environmental Factors
Environmental factors are known to affect incidence rates. When individuals from one community move to
another, they take on the risk of their new environment, often within one generation. For example, a study
of J apanese immigrants to Hawaii revealed that the risk of CRC within this population was similar to that
24of Hawaiians rather than to that of residents of J apan. Environmental factors that have been implicated
in the incidence of CRC include diet, lack of exercise, obesity, smoking, alcohol consumption, and type 2
Consumption of animal fat is associated with CRC. I n the U.S . N urses Health S tudy, 88,751 women were
prospectively followed up for 512,488 person-years. Women who consumed beef, pork, or lamb more than
once per month were 2.5 times more likely to develop CRC compared with women who consumed meat
25less than once per month. No increased risk was found with consumption of vegetable fat. The protective
26effect of fiber on CRC is controversial. Recent meta-analyses have demonstrated that those in the highest
quartile of fiber consumption had a decreased risk of CRC compared with those who were in the lowest
quartile of fiber consumption. However, when controlling for other dietary factors, high fiber failed to
27,28demonstrate any protective effect.
Physical activity is inversely correlated with CRC. I n a prospective study of 45,906 S wedish men, even
29moderate physical activity was associated with a 32% decreased risk of CRC. This relation is stronger in
30men than in women.
Smoking, Alcohol, Obesity, and Diabetes
4CRC has been linked to long-term smoking and alcohol consumption of more than two drinks per day.
Obesity is associated with an increased risk of CRC. A study from Framingham, MassachuseAs,
demonstrated that individuals with a body mass index (BMI ) of more than 30 have a 1.5 to 2.4 times
31 32increased risk of CRC. Furthermore, centripetal obesity is significantly associated with CRC.
Those with type 2 non–insulin-dependent diabetes have an increased risk of developing CRC and a
4poorer prognosis for survival than those without diabetes.
1CRC is the third leading cause of cancer death in the United S tates. A n estimated 49,920 individuals will
4die from CRC in 2008. This accounts for 9% of all cancer-related deaths. The 5-year survival rate is 64%.
From 2000 to 2004, the median age at death for those with CRC was 75 years. CRC decreases life expectancy5by an average of 13 years. Over the past 20 years, the mortality rate from CRC for both women and men
has declined, especially in recent years, most likely as a result of significant advances in treatment
modalities and improved screening (Fig. 1-9). From 1985 to 2002, a 2% per year decrease occurred compared
with a 5% per year decrease from 2002 to 2004. Men are more likely to die from CRC than women (22.7
versus 15.9/100,000). This difference in survival has become less pronounced in recent years owing to a
4greater decline in mortality in men than in women.
FIGURE 1-9 Age-adjusted mortality rates by gender for colon and rectal cancer in the
United States, 1969–2004. (Data from the Surveillance, Epidemiology, and End Results
Program. http://www.seer.cancer.gov. Accessed May 1, 2007.)
Mortality for all racial and ethnic groups has declined except in A merican-I ndian and A laskan natives.
Blacks have a worse prognosis after diagnosis than do whites (see Fig. 1-8). S everal studies have indicated
that these findings are independent of socioeconomic status and stage, indicating that factors beyond
33–35health care access may account for these differences. I n rectal cancer, blacks have a 5-year survival
rate of 41% compared with 50% in whites, and blacks are less likely to complete adjuvant therapy (49%
23versus 61%), which may contribute to their poorer prognosis.
D isease stage directly affects mortality rate in CRC (Fig. 1-10). I f the cancer is diagnosed while still
localized or confined to the primary site (stage I /I I a), survival rate is 90% at 5 years. However, only 39% of
CRC is detected at an early stage. I f the cancer has spread to regional lymph nodes (stage I I I ) or directly
beyond the primary site (stage I I b), the corresponding 5-year survival rate is 67%. I f the cancer has already
4metastasized to distant sites (stage IV), the 5-year survival rate is 10%.FIGURE 1-10 Relative survival rates by stage at diagnosis for colon and rectal cancer
in the United States, 1988–2003. (Data from the Surveillance, Epidemiology, and End
Results Program. http://www.seer.cancer.gov. Accessed May 1, 2007.)
Economic Burden of Disease
The costs of prevention, diagnosis, and treatment of CRC in the United S tates are significant. A s the
American population ages, the economic burden of CRC on the Medicare program and its beneficiaries will
be substantial (Fig. 1-11). Estimated costs in 2000 for the initial diagnosis, ongoing treatment, and last year
36of life phases of care for CRC were approximately $3.2 billion, $1.7 billion, and $2.6 billion, respectively.
By the year 2020, under the “fixed” current incidence, survival rate, and cost scenario, projected costs for
the initial diagnosis, ongoing treatment, and last year of life will be $4.7 billion, $2.6 billion, and $4.0
billion. Under the current trends scenario (decreasing incidence, improving survival, and increasing costs),
the annual costs are estimated to be $5.2 billion, $3.6 billion, and $5.3 billion, respectively. Therefore, at
36least a 50% increase in annual costs for CRC in patients 65 years and older is expected by the year 2020.FIGURE 1-11 Projected costs of colorectal cancer in all phases of care (initial
diagnosis, ongoing treatment, and last year of life) for 2000–2020 (sensitivity
analysis) (From Yabroff R, Mariotto A, Feuer E, Brown M: Projections of the cost
associated with colorectal cancer care in the US for 2000–2020. Health Econ
17(8):947–959, 2007.)
Colorectal cancer is the third most common cancer in the United S tates today. However, the incidence of
CRC has declined in the past two decades. This trend is likely to continue because of early detection and
removal of polyps through screening colonoscopy. S urvival rates are increasing because of earlier diagnosis
and improved treatment modalities. D isparities in prognosis between racial and ethnic groups are
aAributed to complex socioeconomic and genetic factors as well as to differences in access to care. Further
studies to beAer understand these differences are needed to decrease the burden of disease from CRC,
particularly among the population's most disadvantaged groups.
1. Corman M. Colon & Rectal Surgery. 4th ed. Lippincott-Raven: Philadelphia; 1998:884–888.
2. Burkitt DP. Epidemiology of cancer of the colon and rectum, 1971. Dis Colon Rectum.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
4. Cancer Facts and Figures: 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf.
Accessed November 16, 2009.
5. Surveillance, Epidemiology, and End Results Program. Fast Stats. Colon and Rectum Cancer.
Available at: http://seer.cancer.gov/ [Accessed July 26, 2008].
6. Greene F. AJCC Cancer Staging Manual. 6th ed. Springer: New York; 2002.
7. Paquette I, Finlayson SR. Rural versus urban colorectal and lung cancer patients: differences in
stage at presentation. J Am Coll Surg. 2007;205(5):636–641.
8. Gross CP, Andersen MS, Krumholz HM, et al. Relation between Medicare screening reimbursement
and stage at diagnosis for older patients with colon cancer. JAMA. 2006;296(23):2815–2822.
9. Wu XC, Chen VW, Steele B, et al. Subsite-specific incidence rate and stage of disease in colorectal
cancer by race, gender, and age group in the United States, 1992–1997. Cancer. 2001;92:2547–2554.
10. Saltzstein SL, Behling CA, Savides TJ. The relation of age, race, and gender to the subsite location of
colorectal carcinoma. Cancer. 1998;82:1408–1410.
11. Rabeneck L, Davila JA, El-Serag HB. Is there a true “shift” to the right colon in the incidence of
colorectal cancer? Am J Gastroenterol. 2003;98(6):1400–1409.
12. Saltzstein S, Behling C. Age and time as factors in the left-to-right shift of the subsite of colorectal
adenocarcinoma: a study of 213,383 cases from the California cancer registry. J Clin Gastroenterol.
13. Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk ofcolorectal cancer. N Engl J Med. 1994;331(25):1669–1674.
14. Schaffzin DM, Smith LE. Rectal cancer. Cameron JL. Current Surgical Therapy. 8th ed. Elsevier
Mosby: Philadelphia; 2004:216–223.
15. Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel
disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county,
Minnesota. Am J Gastroenterol. 2007;102(4):829–836.
16. Loftus EV Jr. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis
[review]. Gastroenterol Clin North Am. 2006;35(3):517–531.
17. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel
disease: a population-based study. Cancer. 2001;91(4):854–862.
18. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a
metaanalysis. Gut. 2001;48(4):526–535.
19. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A
populationbased study. N Engl J Med. 1990;323(18):1228–1233.
20. Fairley TL, Cardinez CJ, Martin J, et al. Colorectal cancer in U.S. adults younger than 50 years of age,
1998–2001. Cancer. 2006;1(5 Suppl):1153–1161 [107].
21. McCashland TM, Brand R, Lyden E, de Garmo P, CORI Research Project. Gender differences in
colorectal polyps and tumors. Am J Gastroenterol. 2001;96(3):882–886.
22. William S. Who is more prone to develop colorectal cancer? EzineArticles. Available at:
http://ezinearticles.com/?Who-Is-More-Prone-To-Develop-Colorectal-Cancer?&id=51404; July 14,
2005 [Accessed June 24, 2007].
23. Morris AM, Wei Y, Birkmeyer NJ, Birkmeyer JD. Racial disparities in late survival after rectal cancer
surgery. J Am Coll Surg. 2006;203(6):787–794.
24. Maskarinec G, Noh JJ. The effect of migration on cancer incidence among Japanese in Hawaii. Ethn
Dis. 2004;14(3):431–439.
25. Willett WC, Stampfer MJ, Colditz GA, et al. Relation of meat, fat, and fiber intake to the risk of
colon cancer in a prospective study among women. N Engl J Med. 1990;323(24):1664–1672.
26. Baron JA. Dietary fiber and colorectal cancer: an ongoing saga. JAMA. 2005;294(22):2904–2906.
27. Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled
analysis of prospective cohort studies. JAMA. 2005;294(22):2849–2857.
28. Bingham SA, Norat T, Moskal A, et al. Is the association with fiber from foods in colorectal cancer
confounded by folate intake? Cancer Epidemiol Biomarkers Prev. 2005;14(6):1552–1556.
29. Larsson SC, Rutegard J, Bergkvist L, Wolk A. Physical activity, obesity, and risk of colon and rectal
cancer in a cohort of Swedish men. Eur J Cancer. 2006;42(15):2590–2597.
30. Calton BA, James V, Lacey JV, et al. Physical activity and the risk of colon cancer among women: a
prospective cohort study (United States). Int J Cancer. 2006;119(2):385–391.
31. Moore LL, Bradlee ML, Singer MR, et al. BMI and waist circumference as predictors of lifetime colon
cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord. 2004;28(4):559–567.
32. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the
European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst.
33. Morris AM, Billingsley KG, Baxter NN, Baldwin LM. Racial disparities in rectal cancer treatment: a
population-based analysis. Arch Surg. 2004;139(2):151–155.
34. Dominitz J, Samsa G, Landsman P, Provenzale D. Race, treatment, and survival among colorectal
carcinoma patients in an equal-access system. Cancer. 1998;82:2312–2320.
35. Ahuja N, Chang D, Gearhart S. Disparities in colon cancer presentation and in-hospital mortality in
Maryland. A ten year review. Ann Surg Oncol. 2007;14(2):1507–1513.
36. Yabroff R, Mariotto A, Feuer E, Brown M. Projections of the cost associated with colorectal cancer
care in the US for 2000–2020. Health Econ. 2007;17(8):947–959.2
Presentation and Initial
Evaluation of Colorectal Cancer
Susan Tsai, Susan L. Gearhart
• In the United States, nearly 85% of patients with colorectal cancer (CRC) are
symptomatic from their tumors before a diagnosis is made.
• The most common symptoms of CRC include rectal bleeding, abdominal pain,
and change in bowel habits.
• Accurate initial clinical staging allows for the selection of appropriate
stagespecific therapy in the management of CRC.
I n the United S tates, colorectal cancer (CRC) is the third most common cancer
1diagnosis and the second leading cause of cancer death. Because it is so prevalent, as
early as 1980 the A merican Cancer S ociety issued guidelines for CRC screening in
2average-risk adults. A s a result, recent trends in the incidence of and mortality from
CRC reveal declining rates, partly because of effective screening and prevention
3through polypectomy. However, despite prospective randomized trials that have
4demonstrated decreased mortality rate with early detection of CRC, most adults in
the United S tates do not receive regular age- and risk-appropriate screening. Poor
screening participation has been a3 ributed to a variety of factors, including lack of
5–7health insurance and lower socioeconomic status. However, even in the se3 ing of
universal health care, compliance with recommended screening remains low. A
recent retrospective study from British Columbia, Canada, reported that out of 212
patients with CRC, less than 7% were diagnosed via a screening test, and only 15% of
8screeningeligible patients had been screened. S imilarly, in the United S tates, nearly
85% of patients with CRC have symptoms from their tumors before a diagnosis is
9made. Therefore, it remains especially important to recognize the clinical signs and
symptoms of CRC and to appropriately initiate workup when necessary.
The symptoms of CRC are not inherently unique. Patients may present with occult or
symptomatic anemia, bright red blood per rectum, abdominal pain, change in bowel
habits, anorexia, weight loss, nausea, vomiting, or fatigue. Taken in isolation, most of
these signs and symptoms are neither sensitive nor specific and may be present
equally in benign and malignant diseases. However, the clustering of symptoms may